TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
MRNA

Moderna Inc

Healthcare · Biotechnology

182.60$ +5.6% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Income Statement

Moderna Inc (MRNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 145 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement MRNA
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
1,831 2,813 167 221 1,855 956 107 142 1,016 678 389 145 2,228
2,241 929 96 115 514 739 90 119 1,008 452 955 93 2,508
-410 1,884 71 106 1,341 217 17 23 8.0 226 -566 52 -280
1,160 1,406 1,027 1,221 1,137 1,122 856 700 801 775 649 651 2,876
442 266 274 268 281 351 212 230 268 308 173 216 965
1,602 1,878 1,337 1,469 1,411 1,463 1,067 930 268 1,083 822 867 3,040
-2,012 6.0 -1,266 -1,363 -70 -1,246 -1,050 -907 -260 -857 -1,388 -815 -3,320
10 6.0 6.0 6.0 6.0 6.0 1.0 1.0 0.0 8.0 17 17 42
-1,958 70 -1,165 -1,279 21 -1,184 -964 -818 -187 -799 -1,334 -767 -3,087
1,672 -147 10 8.0 -64 7.0 7.0 13 27 9.0 15 64
-3,630 217 -1,175 -1,279 13 -1,120 -971 -825 -200 -826 -1,343 -782 -3,151
-1,699 278 -1,123 -1,232 79 -1,118 -924 -760 -135 -732 -1,258 -704 -2,829

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?